Professional
Added to YB: 2024-10-03
Pitch date: 2024-10-02
RVNC [neutral]
Revance Therapeutics, Inc.
-26.15%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
Market Cap
$609.0M
Pitch Price
$5.20
Price Target
N/A
Dividend
N/A
Sector
Pharmaceuticals
Category
special_situation
Revance (RVNC) Faces Uncertainty: Teoxane Conflict Raises Doubts About Crown Labs Merger
RVNC (merger arb): 28% merger spread due to Teoxane dispute (50% sales). Crown Labs likely mainly wants Daxxify (Botox competitor). Deal may close at lower price if Teoxane issue unresolved. Parties discussing remedies. Teoxane owns 6.3% of RVNC. Large downside if merger fails. More research needed on agreement breaches.
Read full article (2 min)